A D Norden

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence
    A D Norden
    Department of Neurology, Dana Farber Brigham and Women s Cancer Center and Harvard Medical School, SW430B, 44 Binney St, Boston, MA 02115, USA
    Neurology 70:779-87. 2008
  2. pmc Colon perforation during antiangiogenic therapy for malignant glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Neuro Oncol 11:92-5. 2009
  3. doi request reprint Antiangiogenic therapy in malignant gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Oncol 20:652-61. 2008
  4. doi request reprint Novel anti-angiogenic therapies for malignant gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Lancet Neurol 7:1152-60. 2008
  5. doi request reprint An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Neurooncol 92:149-55. 2009
  6. doi request reprint Survival among patients with primary central nervous system lymphoma, 1973-2004
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 44 Binney St, Boston, MA 02115, USA
    J Neurooncol 101:487-93. 2011
  7. doi request reprint Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
    J Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 450 Brookline Avenue, SW 430, Boston, MA 02215, USA
    J Neurooncol 107:133-8. 2012
  8. doi request reprint Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure
    C Lu-Emerson
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 44 Binney Street, SW 430, Boston, MA 02115, USA
    J Neurooncol 104:287-91. 2011

Collaborators

Detail Information

Publications8

  1. doi request reprint Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence
    A D Norden
    Department of Neurology, Dana Farber Brigham and Women s Cancer Center and Harvard Medical School, SW430B, 44 Binney St, Boston, MA 02115, USA
    Neurology 70:779-87. 2008
    ..At recurrence some patients appear to develop nonenhancing infiltrating disease rather than enhancing tumor...
  2. pmc Colon perforation during antiangiogenic therapy for malignant glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Neuro Oncol 11:92-5. 2009
    ..Because GI perforation is a life-threatening yet treatable complication, neurooncologists must have a low threshold to consider it in patients on antiangiogenic drug therapy who present with abdominal pain and other GI complaints...
  3. doi request reprint Antiangiogenic therapy in malignant gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Oncol 20:652-61. 2008
    ..This article reviews the rationale for targeting angiogenesis in malignant gliomas, summarizes relevant clinical trial results, and discusses promising avenues of investigation in antiangiogenic therapy...
  4. doi request reprint Novel anti-angiogenic therapies for malignant gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Lancet Neurol 7:1152-60. 2008
    ..Normalisation of dilated and leaky tumour vasculature might also enable anti-angiogenic therapy to increase the efficacy of radiation therapy and cytotoxic chemotherapy...
  5. doi request reprint An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Neurooncol 92:149-55. 2009
    ..If this conclusion proves correct, progression-free survival may be an inappropriate endpoint for phase II trials of anti-angiogenic therapies...
  6. doi request reprint Survival among patients with primary central nervous system lymphoma, 1973-2004
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 44 Binney St, Boston, MA 02115, USA
    J Neurooncol 101:487-93. 2011
    ..55 [95% CI 4.01, 5.16]). Despite treatment advances, survival among PCNSL patients in the United States remains poor. However, in the subset of PCNSL patients who are HIV-negative, survival has improved over time...
  7. doi request reprint Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
    J Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 450 Brookline Avenue, SW 430, Boston, MA 02215, USA
    J Neurooncol 107:133-8. 2012
    ..The recommended doses for further study are oral panobinostat 30 mg three times per week, every other week, in combination with bevacizumab 10 mg/kg every other week. A phase II clinical trial in recurrent HGG is underway...
  8. doi request reprint Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure
    C Lu-Emerson
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 44 Binney Street, SW 430, Boston, MA 02115, USA
    J Neurooncol 104:287-91. 2011
    ..Treatment was moderately well-tolerated, although one patient sustained a grade 4 intracerebral hemorrhage. Dasatinib in conjunction with bevacizumab does not appear to have activity in patients with recurrent, heavily pretreated GBM...